Skip to main content

Table 1 Baseline demographics and clinical characteristics (Full analysis set)

From: Comparison of peak inspiratory flow rate via the Breezhaler®, Ellipta® and HandiHaler® dry powder inhalers in patients with moderate to very severe COPD: a randomized cross-over trial

Characteristic

Value (N = 97)

Age, years

69.0 ± 8.2

Male, n (%)

72 (74.2)

Race, n (%)

 Caucasian

96 (99.0)

 Asian

1 (1.0)

BMI (kg/m2)

27.0 ± 5.3

Current smoker, n (%)

14 (14.4)

Severity of COPD, n (%)

 

 Moderate

49 (50.5)

 Severe

38 (39.2)

 Very severe

10 (10.3)

Number of COPD exacerbations in the previous year

0.2 ± 0.51

Post-bronchodilator FEV1, % predicted

50.7 ± 15.5

Post-bronchodilator (%) FEV1/FVC

48.3 ± 11.3

  1. Data are presented as mean ± standard deviation, unless otherwise specified. COPD severity is based on GOLD 2014 criteria
  2. BMI body mass index, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, GOLD global initiative for chronic obstructive lung disease